Ann: Immutep Corporate Presentation, page-3

Outlook - 2021/22
One major new trial missing....whats happened to AIPAC P3 (2022)??

My pure speculation :- BMS - either partner up or license efti (or take us out) end of this year or early 2022 (assuming AIPAC 2b OS results compelling of course). Why BMS?

1.Latest Relalimab P3 data - (FDA) has accepted for priority review the Biologics License Application (BLA) for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination, administered as a single infusion. And

2:- Paclitaxel (sold under trade name Taxol® by Bristol-Myers Squibb) is a very effective plant-derived chemotherapy drug used to treat breast (see efti/paclitaxel AIPAC 2b trial), ovarian, lung, bladder, prostate, melanoma, esophageal, as well as other types of solid tumor cancers.

❑ Final data from AIPAC: 2nd OS follow up at SITC
❑ Start & ongoing recruitment of new randomised trial in 1st line HNSCC (TACTI-003) in Q3 2021
✓ Part B of TACTI-002 fully recruited
❑ Recruitment into Part A extension & further data from TACTI-002 in 2021 or early 2022
✓ INSIGHT-003 first patient enrolled in Q3 2021 and first interim results in 2022
❑ Manufacturing scale up to 2,000 L
❑ Ongoing regulatory engagement
❑ Updates from IMP761
❑ Further updates from partnered programs (e.g. GSK, Novartis, EAT COVID, CYTLIMIC and EOC